Novo Nordisk develops inhalable insulin  

Novo Nordisk presents trial results of an inhalable insulin treatment at US conference

Financial daily newspaper Børsen reports that Novo Nordisk, a world leader in diabetes care, has announced trial results of an inhalable insulin formulation at the American Diabetes Association's annual research conference in San Francisco. The new treatment, tested on 107 patients with Type 2 (maturity onset) diabetes, delivers equivalent results to traditionally injected insulin. Dosing is made using an electronic inhaler system which provides very precise blood sugar control. If everything goes according to plan, the new insulin treatment could be on the market in a couple of years.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×